Insights Into Human Intrahepatic NK Cell Function From Single Cell RNA Sequencing Datasets

Gráinne Jameson 1 and Mark W. Robinson 2*

1 School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, 2 Department of Biology, Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Ireland

Diverse populations of natural killer (NK) cells have been identified in circulating peripheral blood and a wide variety of different tissues and organs. These tissue-resident NK cell populations are phenotypically distinct from circulating NK cells, however, functional descriptions of their roles within tissues are lacking. Recent advances in single cell RNA sequencing (scRNA-seq) have enabled detailed transcriptional profiling of tissues at the level of single cells and provide the opportunity to explore NK cell diversity within tissues. This review explores potential novel functions of human liver-resident (lr)NK cells identified in human liver scRNA-seq studies. By comparing these datasets we identified up-regulated and down-regulated genes associated with lrNK cells clusters. These genes encode a number of activating and inhibiting receptors, as well as signal transduction molecules, which highlight potential unique pathways that lrNK cells utilize to respond to stimuli within the human liver. This unique receptor repertoire of lrNK cells may confer the ability to regulate a number of immune cell populations, such as circulating monocytes and T cells, while avoiding activation by liver hepatocytes and Kupffer cells. Validating the expression of these receptors on lrNK cells and the proposed cellular interactions within the human liver will expand our understanding of the liver-specific homeostatic roles of this tissue-resident immune cell population.

Keywords: liver, RNA-seq, liver-resident, intrahepatic, NK cell

INTRODUCTION

Natural Killer Cells: From Blood to Tissues

The phenotype and function of natural killer (NK) cells have been extensively studied in both mice and humans, predominantly utilizing NK cells isolated from circulating peripheral blood (PB). Circulating NK cells account for 5–15% of the total lymphoid population in PB. In humans two functionally distinct subsets of NK cells are recognized, based on their expression of CD56 and CD16: CD56dimCD16+ and CD56brightCD16lo− (1). The CD56dim NK cells represent the majority of circulating NK cells (~90%) and are more cytotoxic than CD56bright NK cells (2).

Circulating NK cells are equipped to recognize and kill both tumor and virally infected cells as well as possessing the ability to regulate other immune cells (3, 4). To carry out their effector functions NK cells have an extensive repertoire of stimulatory, costimulatory and inhibitory receptors but, unlike T and B cells, the genes encoding these receptors do not undergo somatic gene recombination. These NK cell receptors include the killer immunoglobulin-like receptor (KIR) family, the CD94(KLRD1)/NKG2 family of C-type lectins, the natural cytotoxicity receptors (NCR...
and as well as a variety other activating and inhibitory surface receptors, as reviewed previously (5–7). It is the balance of expression of these receptors that is necessary to discriminate between healthy host cells and cells in distress, as well as self and non-self-cells. This balance ensures NK cells remain tolerant of healthy tissue whilst effectively clearing any potential threats, such as viral infection or cancerous cells.

In addition to these circulating NK cell populations it is evident that a variety of tissue-resident NK cell subsets exist (8). Tissue-resident NK cells are enriched in lymphoid tissues, the uterus and the liver, as well as a number of other tissues (9–12). Tissue-resident NK cell populations are predominantly CD56bright in humans and they appear to be phenotypically and functionally distinct from their circulating counterparts (8). In the human liver NK cells constitute up to half of total lymphocytes. The majority of intrahepatic NK cells possess a CD56bright phenotype, however their functional roles within the liver remains unclear (8, 13–16).

THE LIVER AS AN IMMUNOLOGICAL ORGAN

The liver has vital metabolic functions, detoxification functions, and immunological functions (17, 18). It is home to a diverse repertoire of resident immune cells including Kupffer cells (KC), NK cells and other innate and adaptive immune cells which are thought to contribute to maintain hepatic tolerance (19–21). The liver receives up to 80% of its blood supply from the gut via the hepatic portal vein, and this blood contains a high concentration of foreign molecules derived from our diet and gut microbiome. Resident immune cells must remain tolerant to this continuous exposure to harmless dietary and commensal bacterial products, while simultaneously being ready to clear any pathogens, malignant cells or toxic products that it may encounter, ensuring organ homeostasis (18).

Intrahepatic NK Cells

Intrahepatic NK cells were first described in rat livers as “pit cells” in the 1970s after their cytoplasmic granules which resembled grape pits (22). For many years it was known that NK cells were enriched in the liver, however the functional significance of this was unknown (14, 23). Murine studies investigating memory-like NK cell responses identified a population of intrahepatic NK cells in murine livers defined as DX5−CD49a+CXCR6+TRAIL+ (24–28). In 2015 an equivalent human intrahepatic NK cell population was described within hepatic sinusoids defined by the expression of CD49a (29). These CD49a+ intrahepatic NK cells display enhanced pro-inflammatory cytokine responses and memory-like recall responses in in vivo murine and ex vivo human studies (25, 29, 30).

In human liver this CD49a+ intrahepatic NK cell population is highly variable between donors and only represents a minority of the total intrahepatic NK cell population. The majority of human intrahepatic NK cells consist of a CD56bright liver-resident (lr)NK cell population, and are defined phenotypically as CD56brightCXCR6+CD69+Eomes+Tbet+CD49a−CD49e− (11, 13, 16, 29, 31–33). Due to the species specific differences between mice and humans this review will focus only on human studies, with the term “lrNK” being used to specifically refer to the human CD56brightCXCR6+CD69+Eomes+Tbet+CD49a−CD49e− NK cell population.

Using these defined phenotypical markers the effector function of human lrNK cells have been explored in a number of studies (summarized in Table 1). These studies have identified equivalent or reduced cytokine responses and increased degranulation compared PB NK cells and intrahepatic CD56dim populations (Table 1). However, to date these findings are limited to functional assays assessing a limited range of markers, upon stimulation with cytokines or HLA class I deficient immortalized cell lines. In this context, data generated from single cell RNA sequencing (scRNA-seq) studies can provide novel insights into potential roles for human lrNK cells beyond IFN-γ and TNF-α production and cytotoxic responses to cytokine activation or HLA-deficient tumor cells.

SINGLE CELL RNA SEQUENCING ANALYSIS OF INTRAHEPATIC IMMUNE CELL POPULATIONS

Recent advancements in scRNA-seq have provided us with a detailed view of the cellular components that make up the human liver (17, 32, 36–39). A number of studies utilizing scRNA-seq technologies have profiled the human liver (summarized in Table 2) (36–40). These studies have provided a global overview of the unique liver-specific adaptations of both parenchymal and non-parenchymal cells, including tissue-resident immune cells. This data represents an important resource for the international research community.

These scRNA-seq datasets have sampled all tissue-resident immune cell populations (limited only by the number of single cells sequenced in each dataset). However, subsequent validation experiments and functional work in these studies have, out of necessity, focused on only a few selected cell populations present in the human liver. One population currently lacking a detailed interpretation of the transcriptional profiles generated in these datasets is lrNK cells.

In a number of published scRNA-seq studies of the human liver NK cell clusters have been identified although the composition of these NK cell clusters varies between studies (Table 2). The requirement to define clusters based on genes characteristic of specific cell types represents a limitation of scRNA-seq studies. While phenotypic markers have been well defined, the transcriptional profiles that distinguish between immune cell subpopulations, in particular subpopulations of NK cells, lack extended validation. This issue is compounded by the fact that the optimal number of clusters differs depending on the specific research question. The datasets generated by MacParland et al. (37), Aizazani et al. (38), and Zhang et al. (40), all identified a single cluster of NK cells (Table 2). It is likely this single NK cell cluster contains both lrNK cells and circulating NK cells. As such, further analysis of NK cell subpopulations is not possible without reanalysing the raw sequencing datasets in order to generate additional NK cell clusters.
TABLE 1 | Overview of studies that have investigated human lrNK cell function.

| References       | Intrahepatic NK cell subset (A) | Comparison cell subset (B) | Functional difference (A) vs. (B) | Stimulation                                                                 |
|------------------|-------------------------------|-----------------------------|----------------------------------|------------------------------------------------------------------------------|
| Harmon et al. (16) | Hepatic CD56<sup>bright</sup> | PB CD56<sup>bright</sup> | Enhanced CD107α and reduced IFN-γ expression | MHC Class I deficient K562 target cells effector:target 5:1 for 4 h either with or without overnight rhIL-2 priming |
| Hudspeth et al. (13) | Hepatic CD56<sup>bright</sup> | PB CD56<sup>dim</sup> | Similar IFN-γ responses | 20 ng/ml rhIL-12 and 200 U/ml rhIL-2 for 18 h |
| Stegmann et al. (11) | Hepatic CXCR6<sup>+</sup> | Hepatic CXCR6<sup>−</sup> | Lower IFN-γ responses | IL-12/L-18 (5 ng/ml, 50 ng/ml) for 4 h |
| Aw Yeang et al. (33) | Hepatic CD49e<sup>−</sup> | Hepatic CD49e<sup>+</sup> | Similar IFN-γ and TNF-α responses | PMA (20 ng/ml) and ionomycin (1 mg/ml) for 6 h |
| Sun et al. (34) | Hepatic CD160<sup>+</sup> | Hepatic CD160<sup>−</sup> | Higher basal IFN-γ | Unstimulated |
| Lunemann et al. (35) | Hepatic CXCR6<sup>+</sup> CD56<sup>bright</sup> | Hepatic CXCR6<sup>−</sup> CD56<sup>bright</sup> | Reduced IFN-γ and TNF-α | 0.221 cells at an effector:target cell ratio of 5:1 for a total of 6 h |
| Zhao et al. (36) | Hepatic CXCR6<sup>+</sup> CD16<sup>−</sup> | PB and hepatic CXCR6<sup>−</sup> CD16<sup>+</sup> | More CD107α vs. both PB and hepatic CXCR6<sup>−</sup> CD16<sup>+</sup> More IFN-γ vs. hepatic CXCR6<sup>−</sup> CD16<sup>+</sup> | IL-12/L-18 (50 ng/ml) for 6 h |

In contrast both the study by Zhao et al. (36) and the study by Ramachandran et al. (39) identified multiple NK cell clusters (Table 2). The study by Zhao and colleagues identified differentially expressed genes comparing between CXCR6<sup>+</sup> lrNK cells and CX3CR1<sup>+</sup> circulating (c)NK cells (36). The study by Ramachandran and colleagues identified two lrNK cell clusters and one cNK cell cluster, and included lists of differentially expressed genes comparing each individual cluster to all others (39). This study includes liver samples from both healthy controls and patients with liver cirrhosis, and one of the lrNK cell clusters is largely absent in cirrhotic patients highlighting the possibility that NK cell subpopulations may be altered in the diseased liver (39).

To explore the transcriptional profile unique to lrNK cells our review focuses on genes identified in the Ramachandran et al. and Zhao et al. datasets (36, 39). Comparing the lrNK cell and cNK cell clusters between these 2 datasets identifies 180 up-regulated genes associated with lrNK cells, 146 up-regulated genes associated with cNK cells and 19 up-regulated genes shared between lrNK and cNK clusters (Figure 1 and Supplementary Data). Genes up-regulated in lrNK cell clusters include EOMES and CXCR6, which have been validated at a protein level as phenotypic markers of lrNK cells (11, 13, 16). Genes up-regulated in cNK cell clusters include ITGAM, SIPRI, and SELL, which are markers of immune cell migration that are down-regulated at a protein level in tissue-resident immune cell populations (31, 33). A variety of activating and inhibitory receptors, downstream signaling molecules, and effector molecules are differentially expressed between lrNK cells and cNK cells (Figure 1 and Supplementary Data). These differentially regulated genes provide opportunities to identify novel markers of lrNK cells as well as providing intriguing insights into potential functions of lrNK cells within the human liver, which are distinct from cNK cells and extend beyond the recognition of virally infected cells or tumors.

Activating the lrNK Cell Immune Response

A number of genes involved in the activation of NK cells are differentially regulated in lrNK and cNK cells in these scRNA-seq datasets (Figure 1 and Supplementary Data). The lrNK cell clusters up-regulate activating receptor genes CD160, CD27, CD7, IL2RB, TMIGD2, and TNFSF14 as well as SH2D1A, which is involved in signal transduction. In contrast the cNK cell clusters up-regulate activating receptor genes such as CD226, FCGR3A, IL12RB1, and NCR3.

A number of these genes are involved in NK cell interactions with hepatocytes and other immune cell populations. IL2RB encodes the interleukin-2 receptor β-chain (IL-2Rβ); CD122 and is a major marker of NK-committed cells or NK-progenitors, which allows the cells to respond to IL-15 (41). IL-2Ra forms part of the IL-2 as well as the IL-15 receptor (in complex with IL-15Ra) (42). IL-15 is important for NK cell survival, activation and function (43, 44), is strongly expressed in the liver (45–47), and hepatocyte- and Kc-derived IL-15/IL-15Ra directly regulates the homeostasis of liver NK cells via trans-presentation (48). Conversely IL12RB, which encodes IL-12Rβ2, is upregulated on cNK cells and induces IFN-γ production when stimulated by IL-12, highlighting that cNK and lrNK cells are regulated by different cytokines in the liver microenvironment (49).

CD27<sup>+</sup> NK cells are rare in the PB yet are enriched in tissues and associated with lower cytotoxic abilities with reduced granzyme B and perforin in comparison to their CD27<sup>−</sup> counterparts (50). Interestingly, upon binding of its ligand CD70, CD27 is downregulated in an IL-15R-dependent manner suggesting that these lrNK cell’s cytotoxicity is tightly controlled.
### TABLE 2 | Summary of human liver scRNA-seq studies and the NK cell clusters identified.

| References          | Year | Journal                  | Sample type                                    | Technology platform                                                                 | Cells sequenced                      | GEO dataset ID            | NK cell clusters          | Descriptor of gene sets available |
|---------------------|------|--------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------|--------------------------|---------------------------|----------------------------------|
| Zhao et al. (36)    | 2020 | Cell Discovery           | Liver perfusate obtained during orthotopic liver transplantation (n = 3); Fresh | Library = 10X Genomics, Sequenced = Illumina HiSeq XTEN platform                   | Magnetically sorted CD45+ cells      | GSE125188                | Clusters 12 and 13; Figure 2, Supplementary Table 4 | DEG comparing CXCR6+ NK vs. CX3CR1+ NK cell clusters (up-regulated genes in each cluster) |
| Zhang et al. (40)   | 2020 | Journal of Hepatology    | Treatment naïve-ICC tissues and paired adjacent normal samples | Library = 10X Genomics, Sequenced = Illumina Xten or NovaSeq 6000 system             | Viable single cell suspension post tissue digestion                               | GSE138709, GSE142784     | NK cell; Supplementary Table 2        | DEG comparing NK cell cluster vs. all other clusters (no information on up- or down-regulation) |
| Aizarani et al. (38) | 2019 | Nature                   | Healthy liver tissue obtained during resections for CRC metastasis or CC (n = 9); Cryopreserved and fresh | mCEL-Seq2                                                                            | PHH and NPCs or sorted directly after tissue digestion if HCC sample.             | GSE124395                | Cluster 5; Supplementary Table 1   | DEG comparing NK cell cluster vs. all other clusters (up- and down-regulated genes) |
| Ramachandran et al. (39) | 2019 | Nature                   | Healthy liver tissue obtained during resections for CRC metastasis (n = 5) Cirrhotic tissue obtained during orthotopic liver transplantation (n = 5); Fresh | Library = 10X Genomics/Sequenced= Illumina HiSeq 4000                                | Viable CD45+ leucocytes vs. CD45− non-parenchymal cells were sorted via FACS       | GSE136103                | Clusters NK cell (1), NK cell (2), and cNK cell; Extended Data Figure 3E, Supplementary Table 6 | DEG comparing each NK cell cluster vs. all other clusters (up-regulated genes in each cluster) |
| MacParland et al. (37) | 2018 | Nature Communications    | Healthy liver tissue obtained during orthotopic liver transplantation (n = 5); Fresh | Library = 10X Genomics/Sequenced= Illumina HiSeq 2500                                | Total liver homogenate               | GSE115469                | Cluster 8; Supplementary Data 1      | DEG comparing NK cell cluster vs. all other clusters (up- and down-regulated genes) |

CRC, Colorectal cancer; CC, cholangiocarcinoma; PHH, primary human hepatocytes; NPCs, non-parenchymal cells; FACS, fluorescence-activated cell sorting; DEG, differentially-expressed genes.
by their expression of IL-15R and CD27 and the local availability of IL-15 and CD70 (51). In the steady state, CD70 levels are quite low, with tightly regulated expression observed upon activation on T cells, B cells and subsets of DCs (52).

Both CD160 and TNFSF14 (also known as LIGHT) encode proteins capable of binding to herpes virus entry mediator (HVEM; also known as TNFRSF14) (53, 54). HVEM is widely expressed by monocytes, dendritic cells (DC), neutrophils, NK cells, T- and B-cells and downregulated in activated T cells (55, 56). CD160 also binds weakly to classical MHC-I such as HLA-C (57, 58) and the non-classical MHC-I soluble HLA-G (59), while LIGHT also binds to lympho toxin-receptor (LT-R, also known as TNFRSF3) (60).

Engagement of CD160 or LIGHT on PB CD56dim NK cells activates their cytotoxic effector function enhancing NK-mediated lysis of target cells (54, 58, 61), indicating the possibility that NK cells directly regulate HVEM-expressing immune cells in the liver. Both KCs and hepatocytes express LT-R within the liver. The engagement of LIGHT and LT-R on hepatocytes has also been shown to regulate hepatic lipase expression (62) as well as directly regulating hepatocyte proliferation and liver regeneration in response to partial hepatectomy (63–65).

CD7 encodes an early differentiation marker on common lymphoid progenitors and crosslinking of CD7 induces NK cell activation, proliferation, cytokine production and cytotoxicity (66, 67). Ligands for CD7 include SECTM1 (68) (secreted and transmembrane protein 1) and LGALS1 (galectin-1) (69). SECTM1 is highly expressed by epithelial cells and acts as a chemotactant for CD7 expressing cells (70, 71). Galectin-1 is also expressed by epithelial cells as well as T regulatory cells. Galectin-1 is capable of suppressing inflammatory immune responses and is essential for regulating inflammation and hepatocyte proliferation during liver regeneration (72).

SH2D1A encodes the signaling lymphocyte activation molecule (SLAM)-associated protein SAP. This adaptor protein mediates downstream signaling from SLAM family receptors on NK cells leading to stable conjugate formation with target cells via LEA-1 (73) and target cell-directed cytotoxic granule polarization and exocytosis (74). SLAM family receptors are immunoglobulins expressed on a variety of immune cell populations that are activated via homophilic binding (except for SLAMF4/2B4 which binds SLAMF2/CD48) (75).

In addition to these up-regulated genes, a number of activating receptors are expressed by cNK cell but not lrNK cells. cNK cells upregulate FCGR3A which encodes the CD16 protein, a key marker of CD56dim cNK cells, which is responsible for antibody-dependent cell-mediated cytotoxicity (ADCC). NCR3 encodes NKp30 and is upregulated on cNK cells equipping them with anti-tumor specific cytotoxic abilities (76). Likewise the CD226 gene is upregulated on cNK cells and encodes the activating receptor DNAM-1. Interestingly this receptor shares ligands, which include polio virus receptor (PVR/CD155) and Nectin-2 (PVRL2/CD112), with the inhibitory molecule T cell Ig and ITIM domain (TIGIT) that is upregulated in lrNK cells and is discussed in detail in the next section (77). This differential expression emphasizes how certain stimuli can regulate cNK and lrNK cell populations in different directions.

These differentially expressed activating receptor genes highlight the importance of hepatocytes in regulating lrNK cell survival and imply an important role for lrNK cells in regulating liver homeostasis.
Infiltrating immune cell populations within the human liver (Figure 2).

### Inhibiting the IrNK Cell Immune Response

In addition to activating receptors, a number of inhibitory receptors are differentially regulated in IrNK and cNK cells in these scRNA-seq datasets (Figure 1 and Supplementary Data). The IrNK cell clusters up-regulate genes including KLRB1, KLRC1, and TIGIT. Conversely, the cNK cell clusters up-regulate CLEC2D, KIR2DL3, KIR3DL2, and KLRG1.

TIGIT is an inhibitory receptor expressed by T and NK cells and up-regulated upon activation (78, 79). As mentioned previously TIGIT shares its ligands PVR and Nectin-2 with the activating receptor DNAM-1 that is up-regulated in cNK cells (80). TIGIT binds with high affinity to PVR and with lower affinity to Nectin-2, with both interactions resulting in inhibition of NK cell cytotoxicity and IFN-γ production (80–82). Hepatocytes and KCs in the liver express PVR equipping them with the ability to directly inhibit NK cell function (83). Hepatocyte PVR levels are increased during liver regeneration, which is suggested to be a mechanism by which hepatocytes safeguard themselves from TIGIT⁺ NK cell killing (83, 84). DCs express both PVR and Nectin-2, and engagement of PVR with a TIGIT-Fc fusion protein increased DC IL-10 production, which may further suppress NK cell function in the liver (79). Using ligand-receptor pair databases Zhang and colleagues predicted that LAMP3⁺ DCs in the liver interact with conventional circulating NK cells via the activating Nectin2-DNAM-1 axis and with IrNK cells via inhibitory Nectin-2-TIGIT interactions suggesting that liver DCs may be regulating different NK subsets in opposing directions (85, 86).
KLRD1 (CD94) is up-regulated in both cNK and lrNK cells and can combine with KLRC1 (NKG2A) which is specifically up-regulated in lrNK cells. This heterodimeric complex is a C-type lectin receptor and interacts with the non-classical HLA class I molecule HLA-E on target cells resulting in inhibition of NK cell function. High protein levels of NKG2A have been confirmed on CD49e\(^+\) intrahepatic NK cells (29, 35), and NKG2A can be induced by the immunosuppressive cytokines TGF-\(\beta\) and IL-10 which are present at high levels in the liver (87, 88). HLA-E is expressed in the liver by both KCs and hepatocytes providing another molecular pathway through which hepatocytes, and KCs, can inhibit lrNK cell activation. In circulating PB NKG2A\(^+\) NK cells that lack KIR have been shown to kill autologous immature DCs that have reduced HLA-E expression \textit{in vitro} (89), and it is possible lrNK cells are likewise capable of effectively targeting immature DCs that express low levels of HLA-E.

An up-regulation of the \textit{KLRB1} gene in lrNK cells provides a further mechanism that may lead to inhibition of lrNK cell function. Engagement of KLRB1 (CD161) by its ligand lectin-like transcript 1 (LLT1 also known as CLEC2D) inhibits NK cell cytotoxicity and cytokine production (90, 91). LLT1 is expressed by B cells and monocytes and the level of LLT1 decreases on monocytes upon activation (92) but it also increased in cNK cell clusters in these scRNA-seq datasets suggesting that cNK cells may regulate lrNK cell function. While hepatocytes in healthy livers express relatively low levels of LLT1, it is increased in the context of liver cirrhosis and this results in reduced NK cell function (93).

In contrast to lrNK cells, cNK cells express a distinct profile of inhibitory receptors. The scRNA-seq datasets reveal an up-regulation of inhibitory KIRs in cNK cells (\textit{KIR3DL2, KIR2DL3}). This low expression or absence of KIRs on lrNK cells has been validated at the protein level (33). \textit{KLRG1} is also up-regulated in cNK cells. \textit{KLRG1} encodes an inhibitory C-type lectin receptor that recognizes E-cadherin and N-cadherin and inhibits NK cell activation (94).

These differentially expressed inhibitory receptor genes highlight a number of key regulatory mechanisms by which liver hepatocytes and intrahepatic KCs restrain lrNK cell activity and maintain overall organ homeostasis (Figure 2).

**Cytotoxic Machinery**

Upon activation by a target cell, NK cells can release cytotoxic granules and up-regulate death-inducing ligands, each of which result in target cell apoptosis. These scRNA-seq datasets indicate an up-regulation of \textit{GZMK} and \textit{TNFSF10} in lrNK cells, and an up-regulation of \textit{GNYL}, \textit{GZMB}, and \textit{GZMH} in cNK cells (Figure 1 and Supplementary Data).

\textit{TNFSF10} encodes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a transmembrane protein that mediates a death-receptor mediated pathway of cytotoxicity. It has been described as important for both NK cell anti-viral and anti-tumor activity in the liver as it binds to TRAIL death receptors (DR) including DR4 and DR5 on target cells to induce target cell-apoptosis (95–97). Decay receptors (DcR) also exist that do not induce apoptosis and include DcR1 and DcR2. DR4 and DR5 are expressed in by hepatocytes (98), monocytes, monocyte derived macrophages and activated T cells (99).

Granule-mediated cytotoxicity involves the targeted release of secretory granules containing granzymes (e.g., granzyme-A, -B, -H, -K, and -M), together with perforin and granulysin (100). lrNK cells have elevated transcription of \textit{GZMK} which encodes granzyme-K. Granzyme-K has trypsin-like activity and can induce a rapid cell death independently of caspases (100). In contrast cNK cells have elevated expression of \textit{GZMB} encoding for granzyme-B and \textit{GZMH} encoding for granzyme-H. Granzyme-B mediates apoptosis of target cells using caspase-dependent mechanisms (101–103), while granzyme-H can induce cell death independently of caspases (104). Granulysin is a saposin-like protein that has pore forming abilities as well as anti-tumor and anti-microbe cytotoxic activity and is selectively up-regulated in cNK cells (105–107).

The elevated expression of \textit{GZMK} and \textit{TNFSF10} indicates lrNK cells can utilize both death-receptor and granule-mediated cytotoxic pathways to kill target cells, however, they use distinct mediators in comparison to cNK cells where granzyme-B and granulysin are key cytotoxic mediators.

**Regulation of Parenchymal and Non-Parenchymal Cells in the Liver**

In addition to mediating cytotoxic responses, NK cells are also capable of producing a wide variety of immunoregulatory molecules, most notably IFN-\(\gamma\). Within the scRNA-seq datasets lrNK cells upregulate a variety of immunoregulatory genes including \textit{XCLI}, \textit{XCL2}, \textit{CCL3}, and \textit{AREG} which may regulate both parenchymal and non-parenchymal cells in the liver and shape the hepatic immune response (Figure 2).

A number of chemokines were identified in lrNK clusters highlighting potential roles in regulating the migration of other immune cell subsets in the liver. XCL1 and XCL2 bind to the XC chemokine receptor 1 (XCR1), which is selectively expressed by cross-presenting CD141\(^+\) DCs in circulating PB, commonly referred to as cDC1 (108). These cDC1s are functionally equivalent to CD8\(^+\) DC in the mouse, a subset of DC that endocytose stressed cells and dying cells (109, 110) and preferentially present this processed antigen to CD8\(^+\) T cells (111, 112). This XCL1-XCR1 axis may provide lrNK cells the ability to regulate DCs within the human liver (38, 39, 113, 114).

The transcripts for \textit{CCL3}, up-regulated in lrNK cells, and \textit{CCL4}, up-regulated in both cNK and lrNK cells, encode CCL3 (also known as MIP-1\(\gamma\)) and CCL4 (also known as MIP-1\(\beta\)). Both of these chemokines signal via the CCR1 and CCR5 receptors (115) which are expressed by several cell types including monocytes, NK cells and activated CD4\(^+\) and CD8\(^+\) T cells (116, 117). Expression of CCL3 and CCL4 allows lrNK cells to directly regulate migration of myeloid cell populations and T cells into the liver. HSCs also express CCR5 and CCL3-engagement induced their proliferation \textit{in vitro} and implicating the CCL3-CCR5 axis in the progression of liver fibrosis (118, 119).

The liver has a remarkable ability to regenerate itself via hepatocyte proliferation. One of the key pathways involved in regulating hepatocyte proliferation is the epidermal growth
factor (EGF) receptor (EGFR). A number of EGFR ligands are known, one of which is amphiregulin (AREG) (120–122), which is up-regulated at a transcriptional level in lrNK cells. Interestingly, AREG was only identified in lrNK cell cluster from the Ramachandran et al. dataset. This cluster included lrNK cells from both healthy and cirrhotic liver tissues, suggesting this gene may be up-regulated in lrNK cells in the context of liver disease. AREG is a membrane-bound precursor protein that can be processed and secreted to act in a paracrine or autocrine fashion and is involved in in multiple processes including proliferation, apoptosis and migration of both epithelial and immune cells (123). EGFR is expressed by hepatocytes and HSCs in the liver and the AREG-EGFR axis is known to specifically modulate the hepatic acute phase reaction in the liver regeneration process and is essential for normal hepatocellular survival and proliferation (124, 125). Overall, immune cell derived AREG is suggested to be associated with type 2 immune-mediated resistance and tissue protective mechanisms (123, 126, 127).

CONCLUSION

The up-regulation of specific signaling molecules and receptors on lrNK cells and their enrichment in the liver suggest an important liver-specific role for these cells. Attempts to understand these NK cell functions have been limited by the use of functional assays that assess a limited range of markers. Here we show that scRNA-seq datasets can provide novel insights into possible functional roles of human lrNK cells (Figure 2) that may support the development of novel hypotheses to be explored in future functional investigations, once expression at the protein level is validated.

The increased expression of cytotoxic machinery components, including perforin and granzyme-K, equip these lrNK cells with the ability to mediate cytotoxic responses. The activation of this cytotoxicity is tightly controlled by the careful balance of activating and inhibitory receptors, of which lrNK cells express a distinct repertoire. This distinct receptor repertoire may confer the ability to regulate a number of infiltrating immune cell populations within the liver. At the same time this distinct receptor repertoire ensures hepatocytes and KCs can restrain lrNK cell activity and promote organ homeostasis.

Detailed investigations into specific intrahepatic cells that express these receptor ligands and the conditions under which they are induced will aid in our understanding of the liver-specific role of lrNK cells. Validation of potential liver-specific functions of lrNK cells requires a comprehensive analysis of human liver parenchymal and non-parenchymal cell populations, together with the development of novel functional assays. It is evident that a wide diversity of resident intrahepatic NK cell populations exist in the human liver and a detailed understanding of their roles in liver homeostasis and liver disease is essential for our understanding of tissue-resident immune responses within the liver.

AUTHOR CONTRIBUTIONS

GJ and MR contributed equally to the conception and design of the article, interpreting the relevant literature, and drafting and reviewing the manuscript. Both authors contributed to the article and approved the submitted version.

FUNDING

This research was funded by the Health Research Board (Grant number EIA-2017-013).

ACKNOWLEDGMENTS

The authors would like to acknowledge Professor Derek Doherty and Professor Cliona O’Farrelly for critical discussions and feedback on this manuscript. Figures 1, 2 were generated using artwork from smart.servier.com.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.649311/full#supplementary-material

REFERENCES

1. Kiessling R, Klein E, Wiegell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. *Eur J Immunol.* (1975) 5:112–7. doi: 10.1002/eji.1830050208
2. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. *J Immunol.* (1983) 131:1789–96. doi: 10.1002/jbi.351.1.11
3. Jost S, Altfeld M. Control of human viral infections by natural killer cells. *Annu Rev Immunol.* (2013) 31:163–94. doi: 10.1146/annurev-immunol-032712-100001
4. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. *Nature.* (2012) 481:394–8. doi: 10.1038/nature10624
5. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. *Immunity.* (2017) 47:820–33. doi: 10.1016/j.immuni.2017.10.008
6. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. *Sci Transl Med.* (2013) 5:208ra145. doi: 10.1126/scitranslmed.3006702
7. Lanier LL. NK Cell recognition. *Annu Rev Immunol.* (2005) 23:225–74. doi: 10.1146/annurev.immunol.23.021704.115526
8. Björkström NK, Ljunggren H-GG, Michaelsson J. Emerging insights into natural killer cells in human peripheral tissues. *Nat Rev Immun.* (2016) 16:310–20. doi: 10.1038/nri.2016.34
27. Takeda K, Cretney E, Hayakawa Y, Ota T, Akiba H, Ogawasara K, et al. TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood. (2005) 105:2082–9. doi: 10.1182/blood-2004-08-3262

28. Paust S, Gill HS, Wang B-Z, Flynn MP, Moseman EA, Senman B, et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of hapten and viruses. Nat Immunol. (2010) 11:1127–35. doi: 10.1038/ni.1953

29. Marquardt N, Bézat V, Nystrom S, Hengst J,ivarson MA, Kekäläinen E, et al. Cutting edge: identification and characterization of human intrahepatic CD49a^+ NK cells. J Immunol. (2015) 194:2467–71. doi: 10.4049/jimmunol.1402756

30. Stary V, Pandey RV, Strobl J, Kleiss L, Starlinger P, Pereyra D, et al. A discrete subset of epigenetically primed human NK cells mediates antigen-specific immune responses. Sci Immunol. (2020) 5:eaba6232. doi: 10.1126/sciimmunol.aba6232

31. Cuff AO, Robertson FP, Stegmann KA, Pallett LJ, Maini MK, Davidson BR, et al. Eomes NK Cells in human liver are long-lived and do not recirculate but can be replenished from the circulation. J Immunol. (2016) 197:4283–91. doi: 10.4049/jimmunol.1601424

32. Filipovic I, Sönnerborg I, Strunz B, Friberg D, Cornillet M, Hertwig L, et al. 29-Color flow cytometry: un-raveling human liver NK cell repertoire diversity. Front Immunol. (2019) 10:2692. doi: 10.3389/fimmu.2019.02692

33. Aw Yeang HK, Piersma SJ, Lin Y, Yang L, Malkova ON, Miner C, et al. Cutting edge: human CD49e^+ NK cells are tissue resident in the liver. J Immunol. (2017) 198:1417–22. doi: 10.4049/jimmunol.1601818

34. Sun H, Xu J, Huang Q, Huang M, Li K, Qu K, et al. Reduced CD160 expression contributes to impaired NK-cell function and poor clinical outcomes in patients with HCC. Cancer Res. (2018) 78:6581–93. doi: 10.1158/0008-5472.CAN-18-1049

35. Lunemann S, Langeneckert AE, Martrus G, HESS LU, Ziegler S, et al. Single-cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun. (2018) 9:4383. doi: 10.1038/s41467-018-06318-7

36. Aizazani N, Saviano A, Sagar, Mailll L, Durand S, Herman JS, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. (2019) 572:199–204. doi: 10.1038/s41586-019-0837-9

37. Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. (2019) 575:512–8. doi: 10.1038/s41586-019-06613

38. Zhang M, Yang H, Wan L, Wang Z, Wang H, Ge C, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. (2020) 73:1118–30. doi: 10.1016/j.jhep.2020.05.039

39. Freud AG, Becknell B, Roychowdhury S, Hao HC, Ferketik AK, Nuovo GJ, et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity. (2005) 22:295–304. doi: 10.1016/j.immuni.2005.01.013

40. Wu Y, Tian Z, Wei H. Developmental and functional control of natural killer cells by cytokines. Front Immunol. (2017) 8:930. doi: 10.3389/fimmu.2017.00930

41. Dunne J, Lynch S, O’Farrell C, Todyr Y, Hegarty JE, Feighery C, et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol. (2001) 167:3129–38. doi: 10.4049/jimmunol.167.6.3129

42. Eason NJ, Stegmann KA, Swadling L, Pallett LJ, Burton AR, Odero D, et al. IL-15 Overcomes hepatocellular carcinoma-induced NK cell dysfunction. Front Immunol. (2018) 9:1009. doi: 10.3389/fimmu.2018.01009

43. Golden-Mason L, Kelly AM, Doherty DG, Traynor O, McIntee G, et al. Hepatic interleukin 15 (IL-15) expression: Implications for local NK/NKT cell homeostasis and development. Clin Exp Immunol. (2004) 138:94–101. doi: 10.1111/j.1365-2249.2004.02586.x
46. Stienstra R, Saudale F, Duval C, Keshkar S, Groener JEM, Van Rooijen N, et al. Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity. *Hepatology*. (2010) 51:151–22. doi: 10.1002/hep.23337

47. Cui G, Hara T, Simmons S, Wagatsuma K, Abe A, Miyachi H, et al. Characterization of the IL-15 niche in primary and secondary lymphoid organs in vivo. *Proc Natl Acad Sci U S A*. (2014) 111:1915–20. doi: 10.1073/pnas.1318281111

48. Cepero-Donates Y, Rakotoarivelo V, Mayhue M, Ma A, Chen YG, Zwirner NW, Ziblat A. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: The case of IL-27. *Front Immunol.* (2017) 8:25. doi: 10.3389/fimmu.2017.00025

49. Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. *Immunology*. (2011) 133:350–9. doi: 10.1111/j.1365-2567.2011.03446.x

50. Vossen MTM, Matmati M, Hertoghs KML, Baars PA, Gent M-R, Leclercq G, et al. CD27 defines phenotypically and functionally different human NK cell subsets. *J Immunol*. (2008) 180:3739–45. doi: 10.4049/jimmunol.180.6.3739

51. Vossen MTM, Matmati M, Hertoghs KML, Baars PA, Gent M-R, Leclercq G, et al. CD27 defines phenotypically and functionally different human NK cell subsets. *J Immunol*. (2008) 180:3739–45. doi: 10.4049/jimmunol.180.6.3739

52. Sedý JR, Bjordahl RL, Bekaris V, Macauley MG, Ware BC, Norris PS, et al. CD160 Activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. *J Immunol*. (2013) 191:828–36. doi: 10.4049/jimmunol.1300894

53. Nuriev RL, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. *J Immunol*. (2013) 180:138–49. doi: 10.1074/jimmunol.201205.0509

54. Steinberg MW, Cheung TC, Ware CF. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. *Immunol. Rev.* (2011) 244:169–87. doi: 10.1111/j.1600-065X.2011.01064.x

55. Le Routillier P, Barakonyi A, Giustiniani J, Lenfant F, Marie-Cardine A, Aguerre-Girr M, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. *Proc Natl Acad Sci U S A*. (2002) 99:16963–8. doi: 10.1073/pnas.162681098

56. Barakonyi A, Rabot M, Marie-Cardine A, Aguerre-Girr M, Polgar B, Schiavon V, et al. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. *J Immunol*. (2004) 173:5349–54. doi: 10.4049/jimmunol.173.9.5349

57. Pons F, Chabot S, Cartwright JE, Lenfant F, L’Espaqui F, Giustiniani J, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. *Blood*. (2006) 108:2686–15. doi: 10.1182/blood-2005-12-101991

58. Rooney IA, Butovich KD, Glass AA, Borboroglu S, Benedict CA, Whitbeck JC, et al. The lymphombox-β receptor is necessary and sufficient for LIC mediates adhesion, activation and inhibition via c1s and trans interactions. *Clin Immunol*. (2019) 204:37–42. doi: 10.1016/j.clim.2018.10.011

59. von Strandmann EP, Schatnyeva O, Hansen HP. NKp30 and its ligands: receptors. *Clin Immunol*. (2015) 153:243–54. doi: 10.1038/nri3799

60. von Strandmann EP, Schatnyeva O, Hansen HP. NKp30 and its ligands: receptors. *Clin Immunol*. (2015) 153:243–54. doi: 10.1038/nri3799

61. Holmes TD, Wilson EB, Black EY, Benest A V, Vaz C, Tan B, et al. Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT. *Proc Natl Acad Sci U S A*. (2014) 111:E6888–96. doi: 10.1073/pnas.1411072112

62. Jo JC, Wang Y, Tumanov AV, Banjii M, Yao Z, Reardon CA, et al. Lymphotoxin β receptor-dependent control of lipid homeostasis. *Science*. (2007) 316:285–8. doi: 10.1126/science.1137221

63. Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu Y-X. Contribution of the lymphoxygen β receptor to liver regeneration. *J Immunol*. (2005) 175:1295–300. doi: 10.4049/jimmunol.175.2.1295

64. Behnke K, Sorg VR, Heribian D, Häussinger D, Keitel V, Pfeffer K. The role of the lymphoxygen β receptor (LTβR) in hepatocyte-mediated liver regeneration. *Eur J Med Res*. (2019) 14(Suppl. 1):S3. doi: 10.1186/s40748-783X-19-S1-53

65. Rabinovich H, Lin WC, Herberman RB, Whiteside TL. Signalling via CD7 molecules on human NK cells. Induction of tyrosine phosphorylation and beta 1 integrin-mediated adhesion to fibronectin. *J Immunol*. (1994) 153:3504–13.
polarization and cytotoxicity of NK cells. *Cell Death Differ.* (2013) 20:456–64. doi: 10.1038/cdd.2012.141

82. Li M, Xia P, Du Y, Liu S, Huang G, Chen J, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/polvirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via IL-10 and IL-2-mediated negative signaling. *J Biol Chem.* (2014) 289:15647–57. doi: 10.1074/jbc.M114.572420

83. Bi J, Zheng X, Chen Y, Wei H, Sun R, Tian Z. TIGIT safeguards liver regeneration through regulating natural killer cell-hepatectomy crosstalk. *Hepatology.* (2014) 60:1388–99. doi: 10.1002/hep.27245

84. Erickson BM, Thompson NL, Hixson DC. Tightly regulated induction of IFN-γ. *Hepatology.* (2006) 43:325–34. doi: 10.1002/hep.21021

85. Zhang Q, He Y, Luo N, Peng J, Ren X, Zhang Correspondence Z. Landscape of antiviral response by natural killer cells through TRAIL gene induction by IFN-γ. *J Immunol.* (2001) 31:3138–46. doi: 10.1002/jimm.1521-3

86. Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. KLRG1 binds cadherins and preferentially associates with SHIP-1. *J Biol Chem.* (2014) 289:17647–57. doi: 10.1074/jbc.M114.572420

87. Jinushi M, Takehara T, Tatsumi T, Yamaguchi S, Sakamori R, Hiramatsu N, et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4+ CD25+ T cells with PD-1-dependent regulatory activities. *Immunology.* (2007) 120:73–82. doi: 10.1111/j.1365-2141.2006.02479.x

88. Lassen MG, Lukens JR, Dolina JS, Brown MG, Hahn YS. Intrahepatic IL-10 Maintains NKG2A+ Ly49– liver NK cells in a functionally hyporesponsive state. *J Immunol.* (2010) 184:2693–701. doi: 10.4049/jimmunol.0901362

89. Della Chiesa M, Vitale M, Carlo magno S, Ferlazzo G, Moretta L, Moretta A, et al. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. *Euro J Immunol.* (2003) 33:1657–66. doi: 10.1002/eji.200323986

90. Allemi H, Prod’homme V, Dumaurier M-J, Retiere C, Poupon R, et al. KLRG1 binds cadherins and preferentially associates with SHIP-1. *J Biol Chem.* (2014) 289:17647–57. doi: 10.1074/jbc.M114.572420

91. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble CD80+ dendritic cells is attributable to their ability to internalize dead cells. *Immuno logy.* (2002) 107:183–9. doi: 10.1046/j.1365-2567.2002.01513.x

92. Iyoda T, Shimoyama S, Liu K, Omata Y, Akiyama Y, Maeda Y, et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. *J Exp Med.* (2002) 195:1289–302. doi: 10.1084/jem.20020161

93. Schulz O, Reis E Sousa C. Cross-presentation of cell-associated antigens by CD8α+ dendritic cells is attributable to their ability to internalize dead cells. *Immuno logy.* (2002) 107:183–9. doi: 10.1046/j.1365-2567.2002.01513.x

94. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. *Annu Rev Immunol.* (2014) 32:659–702. doi: 10.1146/annurev-immunol-032713-021414

95. Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, et al. Regions in β-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. *Cell.* (1996) 87:437–46. doi: 10.1016/S0092-8674(96)03381-C

96. Blum EM, Bartynski KL, Avalos BR, Caligiuri MA. Human natural killer cells produce abundant macrophage inflammatory protein-1α in response to monocyte-derived cytokines. *J Clin Invest.* (1996) 97:2722–7. doi: 10.1172/JCI118726
118. Heinrichs D, Berres ML, Nellen A, Fischer P, Scholten D, Trautwein C, et al. The chemokine CCL3 promotes experimental liver fibrosis in mice. *PLoS ONE*. (2013) 8:66106. doi: 10.1371/journal.pone.0066106

119. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. *J Clin Invest*. (2009) 119:1858–70. doi: 10.1172/JCI37444

120. Santamaría E, Rodríguez-Ortigosa CM, Uriarte I, Latasa MU, Urtasun R, Alvarez-Sola G, et al. The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis. *Hepatology*. (2019) 69:1632–47. doi: 10.1002/hep.30348

121. Berasain C, García-Trevijano ER, Castillo J, Erroba E, Lee DC, Prieto J, et al. Amphiregulin: an early trigger of liver regeneration in mice. *Gastroenterology*. (2005) 128:424–32. doi: 10.1053/j.gastro.2004.11.006

122. Michalopoulos GK, Khan Z. Liver regeneration, growth factors, and amphiregulin. *Gastroenterology*. (2005). 128:503–6. doi: 10.1053/j.gastro.2004.12.039

123. Berasain C, Avila MA. Amphiregulin. *Semin Cell Dev Biol*. (2014) 28:31–41. doi: 10.1016/j.semcdb.2014.01.005

124. Carver RS, Stevenson MC, Scheving LA, Russell WE. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. *Gastroenterology*. (2002) 123:2017–27. doi: 10.1053/gast.2002.37060

125. Pardo-Saganta A, Latasa MU, Castillo J, Alvarez-Asiain L, Perugorría MJ, Sarobe P, et al. The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression. *J Hepatol*. (2009) 51:1010–20. doi: 10.1016/j.jhep.2009.06.030

126. Zaiss DMW, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. *Immunity*. (2015) 42:216–26. doi: 10.1016/j.immuni.2015.01.020

127. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JKM, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. *Nature*. (2009) 457:722–5. doi: 10.1038/nature07537

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Jameson and Robinson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.